Skip to content

Author

K. Docherty

We have 11 of 273 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 6518: Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF

Background: The Kidney Failure Risk Equation (KFRE) is recommended in international guidelines for estimating the risk of kidney failure in patients with chronic kidney disease (CKD). The prognostic relevance of the KFRE has not been described in patients with heart failure and mildly reduced or preserved ejection f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Oct 2026

Lung ultrasound in ambulatory adults with HFpEF: Association between pulmonary congestion and one-year outcomes

Early detection of congestion among adults with heart failure and preserved ejection fraction (HFpEF) is critical to optimize therapy prior to overt decompensation, yet traditional tools are insensitive. We sought to examine the association between B-lines on lung ultrasound (LUS) in ambulatory adults with HFpEF...

Elke Platz, K. McDowell, Deepak K. Gupta et al. · 0 citations
Open access Oct 2026

Simplified BMI-stratified diagnostic NT-proBNP thresholds in patients with HFpEF

Obesity is associated with lower natriuretic peptide concentrations, potentially reducing the diagnostic accuracy of N-terminal pro–B-type natriuretic peptide (NT-proBNP) for heart failure with preserved ejection fraction (HFpEF). Several body mass index (BMI)–adjusted NT-proBNP thresholds have been proposed, but...

R. Ono, R. Campbell, A. Henderson et al. · 0 citations
Open access Oct 2026

Validation of an AI-ECG tool to detect left ventricular systolic dysfunction in community-based patients with suspected heart failure and elevated NT-proBNP

Many patients with suspected heart failure (HF) experience long waits for echocardiography, despite risk-stratification using natriuretic peptides (NP). Prioritising echocardiography in those who are likely to have HF with reduced ejection fraction (HFrEF) would be of value in many healthcare settings and to pati...

U. Razzaq, K. Docherty, A. Morton et al. · 0 citations
Review Open access Oct 2026

Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure.

BACKGROUND Patients hospitalized for heart failure often require prolonged intravenous diuretic therapy, contributing to costs and risks associated with inpatient care. OBJECTIVES We evaluated whether an early discharge strategy using subcutaneous furosemide delivered via a wearable minipump could increase days alive...

Ross T. Campbell, J. Osmanska, K. Docherty et al. · 1 citation
Open access Oct 2026

Effects of empagliflozin according to background angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction (SUGAR-DM-HF)

The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces left ventricular (LV) volumes in heart failure with reduced ejection fraction (HFrEF). Whether this effect is additive to optimal background guideline-recommended therapy is unknown. To evaluate the effects of empagliflozin according to key...

M. Lee, C. Berry, R. Campbell et al. · 0 citations
Open access Aug 2026

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial.

BACKGROUND The HFpEF-ABA score is a simple diagnostic tool developed to estimate the probability of heart failure with preserved ejection fraction (HFpEF) using age, body mass index, and history of atrial fibrillation. OBJECTIVES This study aims to evaluate the HFpEF-ABA score in patients with confirmed heart failure...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Aug 2026

Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF).

BACKGROUND Heart failure (HF) is a common cardiovascular complication of diabetes. Early identification of unrecognized HF enables initiation of disease-modifying therapies. International diabetes and HF clinical practice guidelines are inconsistent with respect to recommendations for screening for HF in people with di...

D. Taylor-Sweet, M. Petrie, Gemma Mckinley et al. · 1 citation
Open access Aug 2026

Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study.

BACKGROUND AND AIMS N-terminal pro-B-type natriuretic peptide (NT-proBNP) is recommended to guide echocardiography referral in community-based patients with suspected heart failure (HF), but diagnostic performance is influenced by individual characteristics including age, ethnicity, kidney function, cardiac rhythm, and...

K. Docherty, B. Heywood, L. Anderson et al. · 0 citations
Open access Aug 2026

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

A prediction model is developed to estimate the short-term treatment effects of combination medical therapy on systolic blood pressure (SBP), diastolic BP, estimated glomerular filtration rate (eGFR) and serum potassium and individualized estimates of the expected treatment effect are provided.

Nelson Wang, B. Claggett, M. Pfeffer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.